{"id":"s6g5t-3","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Skin irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action is not fully understood, but it is believed to work by reducing sebum production and preventing comedone formation. This leads to a decrease in acne lesions and an improvement in overall skin health.","oneSentence":"S6G5T-3 is a topical gel formulation of a proprietary molecule that targets the sebaceous glands to treat acne.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:13.665Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT03761810","phase":"PHASE3","title":"A Study of S6G5T3 in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2018-12-14","conditions":"Acne Vulgaris","enrollment":434},{"nctId":"NCT03761784","phase":"PHASE3","title":"A Study of S6G5T-3 in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2018-12-21","conditions":"Acne Vulgaris","enrollment":424},{"nctId":"NCT04059523","phase":"PHASE1","title":"MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2019-06-27","conditions":"Acne Vulgaris","enrollment":62},{"nctId":"NCT02661958","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2016-05","conditions":"Acne Vulgaris","enrollment":726}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Encapsulated Benzoyl Peroxide (E-BPO) and Encapsulated Tretinoin (E-ATRA) Cream, (E-BPO/E-ATRA Cream)"],"phase":"phase_3","status":"active","brandName":"S6G5T-3","genericName":"S6G5T-3","companyName":"Sol-Gel Technologies, Ltd.","companyId":"sol-gel-technologies-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S6G5T-3 is a compound being studied for the treatment of Acne Vulgaris, as part of a Phase 1b clinical trial (NCT04059523). It is an enzyme modality, specifically a sulfoglucosamine sulfatase, which is involved in breaking down sulfated compounds.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}